RPSA as a Potential Prognostic Biomarker of Pancreatic Cancer

Pancreatic Ductal Adenocarcinoma (PDAC) Clinical Trial

— PaCaBioMarkeR  

Official title:

RPSA as a Potential Prognostic Biomarker of PDAC

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04575363
• Other study ID #: PA20113
• Status: Recruiting
• Phase: N/A
• Start date: October 18, 2021
• Est. completion date: October 18, 2027

Study information

• Verified date: November 2023
• Source: CHU de Reims
• Contact: Jean-Baptiste OUDART
• Phone: 03 10 73 62 87
• Email: joudart[@]chu-reims.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

PDAC (Pancreatic ductal adenocarcinoma) represents 90% of pancreatic tumors. The prognosis of PDAC remains poor at this time. Its management is based on surgery for early stages, associated with neoadjuvant and adjuvant chemotherapy. However, around 80% of patients will relapse after surgery. There is a lack of efficient biological biomarkers of PDAC, especially for prognosis. To date, CA19-9 is commonly used despite its lack of sensitivity and specificity.

Ribosomal protein SA (RPSA) is a transmembrane receptor localized at the cell surface but also in the cytosolic and nuclear regions. RPSA interacts with many proteins in the extracellular matrix (ECM), including laminin-1 and elastin. RPSA in involved in different cellular functions such as cell adhesion, migration, proliferation and differentiation. The expression of RPSA is increased in many cancers including breast, lung, prostate, pancreatic, etc. It could represent a molecular biomarker of tumor invasion and metastatic abilities. Moreover, the concentration of RPSA could be measured in the serum of patients with PDAC. Recent data suggest that a modification of the RPSA concentration could be a prognostic biomarker of PDAC.

Description:

The aim of this study is to explore the potential implication of RPSA as prognostic biomarker of PDAC.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 90
• Est. completion date: October 18, 2027
• Est. primary completion date: October 18, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

inclusion criteria :

• Patients treated at the Reims University Hospital for a resectable or potentially resectable pancreatic tumor, with or without neoadjuvant chemotherapy

• Adults (aged more than 18 years old)

• Patients who have signed the informed consent form

exclusion criteria :

• Patients with a prior history of cancer (excluding basal cell carcinoma or in situ cervical cancer that received conventional cancer treatment).

• Minors

• Patients for whom PDAC is not the retained diagnosis

Related Conditions & MeSH terms

• Adenocarcinoma
• Pancreatic Ductal Adenocarcinoma (PDAC)

Intervention

Other:
• Blood sample
Blood sample

Locations

Country	Name	City	State
France	Damien JOLLY	Reims

Sponsors (1)

Lead Sponsor	Collaborator
CHU de Reims

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	RPSA serum concentration	The RPSA serum concentration is assessed with commercially available RPSA ELISA assay (MyBioSource - MBS9137288).	Day 0